Blog

Lawsuit Blames Hair Loss Drug For Sexual Dysfunction And Mental Problems

March 03, 2011|By RINKER BUCK, The Hartford Courant

A Connecticut law firm has filed a lawsuit against pharmaceutical manufacturer Merck & Co. on behalf of men who have taken Propecia, a prescription drug that combats hair loss but, its critics say, can also cause severe side effects such as sexual dysfunction and mental impairment.

Attorney Edward Jazlowiecki of Bristol has joined two other firms, in New Jersey and New York, in filing the suit, which alleges that Merck has failed to fully disclose the serious side effects of Propecia and failed to adjust its warnings in the American market even after European regulators forced the company to carry a stronger warning label.

Propecia, which is also marketed under the brand name Proscar, was originally introduced to treat men with enlarged prostates, but it won FDA approval in 1997 for the treatment of male pattern hair loss after patients noticed its restorative powers with hair. The drug’s active ingredient is finasteride, which can help reduce the levels of the substance on the scalp that leads to hair loss.

But in many men, Jazlowiecki said, finasteride also reduces sexual function and leads to mental and emotional symptoms like anxiety attacks and insomnia that do not go away years after men stop using the drug.

“The same mechanism in the hormone system that controls hair loss also controls sexual function and a patient’s mental state, and this drug has had devastating effects and destroyed the lives of men who have taken it,” Jazlowiecki said. “Merck knew this, and their claims that the negative effects of the drug go away once you stop using it are false. The damage to these men appears to be permanent, even after five years of taking the drug.”

When contacted by The Courant, Merck released a statement that said, “The company intends to vigorously defend against the lawsuit.”

Jazlowiecki said that one of the plaintiffs in his suit suffered such severe symptoms that his wife left him, and that another plaintiff suffered from a loss of concentration that forced him to drop out of law school. Jazlowiecki’s complaint, filed in U.S. District Court in New Jersey, where Merck’s U.S. headquarters are located, also quotes American and European doctors who have passionately argued against the drug, citing many of the severe side effects listed in the lawsuit.

Similar experiences are described on a website devoted to men who have suffered side effects from the drug, http://www.propeciahelp.com.

Do you have Hair Loss Problems, read our Hair Loss Help

Hair loss at 20 signals greater prostate cancer risk

Men who start balding at 20 may be at a greater risk of developing prostate cancer than their non-balding brethren, according to a study published in the Annals of Oncology.

Comparing nearly 700 men in their late 60s, with and without prostate cancer, the study states that those with the disease were twice as likely to have started balding in their 20s. However, early hair loss is not associated with early onset of cancer or a more aggressive tumor.

Men whose hair begins to thin in their 30s and 40s don’t face the similar risk.

Prostate screening
The study authors are not sure if prostate screening helps men with or without hair loss.

The study author, Dr. Philippe Giraud, from the European Georges Pompidou Hospital in Paris, noted, “At present, there is no hard evidence to show any benefit from screening the general population for prostate cancer.”

He says there needs to be a way of identifying men who are at high risk of developing prostate cancer.

Link between hair loss and prostate cancer
Baldness affects at least half of men and is very common.

Although the link between hair loss and prostate cancer has been reported for the first time, an earlier research has associated baldness with higher levels of androgenic hormones — like testosterone — which fuel the growth of prostate cancer.

The drug finasteride stops the conversion of testosterone to an androgen, which causes hair loss, and so is used to treat baldness. The study notes finasteride also contributed to lower incidence of prostate cancer.

The study
In order to explore the possible connection between balding and prostate cancer, the team recruited men with and without prostate cancer.

First group comprised 388 men who were diagnosed with prostate cancer between the ages of 46 and 84. The team spent more than two years analyzing the progress of the disease and the patterns of hair loss. The investigators gleaned from the men such details as any previous balding experience, when their hair loss started, and more importantly, what type of hair loss occurred at 20, 30, and 40.

The second group of 281 healthy men was recruited for comparison.

In the comparative study, the team found some startling results: 37 of the prostate cancer patients had some kind of hair loss at the age of 20, while only 14 of the healthy men experienced the same. The hair loss ranged from a receding hair line to a bald spot at the top of the head, or a combination of both.

The study authors conclude that any form of hair loss at 20 is linked to a doubling of prostate cancer risk.

The researchers still expressed caution about the link between prostate cancer and baldness.

Word of caution
Although the study is food for thought, it is not conclusive.

Dr. Nelson Neal Stone, a clinical professor of urology and radiation oncology at Mount Sinai School of Medicine in New York City, said, “first of all, the number of patients involved is very low, which makes interpretation and application to the general population very risky.”

In addition to that, scientists know that genetic factors are involved in the prevalence of prostate cancer.

“So, you have two genetically related factors that there may be an association from, and each may be linked to early high male hormone levels. So it may be a hormonally related situation. But it’s very hard to prove,” Stone said.

Further investigations are required to prove the association.

Dr. Philippe Giraud, the study author, said, “Balding at the age of 20 may be one of these easily identifiable risk factors, and more work needs to be done now to confirm this.”

Do you have Hair Loss Problems, read our Hair Loss Help

Scientists accidentally discover possible cure for hair loss

UCLA scientists may have found a possible solution to an age-old problem – hair loss.

The researchers, along with the Veterans Administration that was investigating how stress affects gastrointestinal function may have found a chemical compound that induces hair growth by blocking a stress-related hormone associated with hair loss.

“Our findings show that a short-duration treatment with this compound causes an astounding long-term hair regrowth in chronically stressed mutant mice,” said Million Mulugeta, an adjunct professor of medicine in the division of digestive diseases.

“This could open new venues to treat hair loss in humans through the modulation of the stress hormone receptors, particularly hair loss related to chronic stress and aging,” he added.

With age, mice produced a stress hormone called corticotrophin-releasing factor, or CRF that is associated with hair loss. The Salk Institute researchers had developed the chemical compound, a peptide called astressin-B, and described its ability to block the action of CRF.

About three months later, the investigators found that they had regrown hair on their previously bald backs.

“When we analyzed the identification number of the mice that had grown hair we found that, indeed, the astressin-B peptide was responsible for the remarkable hair growth in the bald mice,” Mulugeta said.

Just one shot per day for five consecutive days maintained the effects for up to four months.

The team added that only further studies would tell if the effect would be seen in humans too.

The find is published in the online journal PLoS One. (ANI)

All About: Washington, Veterans Administration, UCLA, Salk Institute

Do you have Hair Loss Problems, read our Hair Loss Help

Device may limit chemotherapy side-effects

Scientists have developed a micro device that could be used to limit the side-effects of chemotherapy in cancer patients.

Chemotherapy is used to treat cancerous tumours

Edinburgh University has created the unit, which triggers reactions in cells, enabling cancer drugs to be activated at the site of a tumour.

Scientists believe it could protect cancer patients from hair loss, sickness and weakened immune systems.

The device uses tiny amounts of the metal palladium to trigger reactions.

The metal particles are covered in a coating to allow it to penetrate the cells without causing damage.

Experiments have shown specific cell functions could be activated without any impact on normal cell activity such as producing proteins.

It is hoped further work will see the technique used to activate cancer drugs at the site of the tumour.

Research leaders stressed the work, carried out with the Universiti Kebangsaan Malaysia, is at an early stage.

Professor Mark Bradley of Edinburgh University’s school of chemistry, who led the research, said: “This technique potentially gives us the ability to deliver drugs to exactly where they are needed, for example in targeting cancerous tumours.”

Do you have Hair Loss Problems, read our Hair Loss Help

What to do about hair loss

Our experts answer your questions . This week: how to prevent hair loss

Q My son, who is 32, has hair loss at the temples and now loss on his crown. He is self-conscious about this and I wonder if there is anything he could do to help prevent further loss. Jane Butler, email

DR DAN RUTHERFORD WRITES:

A Loss of hair on the crown and at the front hairline is the typical pattern of male hair loss, but a lot can be done about it now.

The hair-growing follicles in these scalp areas are particularly sensitive to testosterone, which slowly reduces their hair-producing activity until they finally switch off at some point in most men. This sensitivity is programmed into the follicle rather than the scalp area, which is why moving follicles from the sides and back of the scalp, which do not have this sensitivity, can be an effective long-term solution.

There are, however, many options other than transplantation. Finasteride is an anti-testosterone drug used mainly to reduce the size of enlarged prostate glands in older men, but at a lower dose (Propecia) it is licensed to slow the rate of hair loss in males. It has a good rate of effectiveness and causes few side-effects, even when used over several years. It comes in tablet form, but is not available via the NHS, so needs to be obtained by private prescription (which can be written by an NHS GP, if he or she is willing).

Minoxidil is a drug originally discovered in the search for high-blood-pressure treatments but found to have a side effect of stimulating hair growth. It comes in a solution (Regaine) and is also non-prescribable on the NHS, but can be bought without prescription from a pharmacy (the five per cent strength is more effective than the two per cent, which is being phased out).

Both Propecia and Regaine can be combined if desired, although there is little formal research on the extra benefit achievable. Both need to be continued long-term as they work only as long as they are used.

Other treatments that use hair-weaving or other cosmetic techniques are now highly developed and can also give excellent results. See Do you have Hair Loss Problems, read our Hair Loss Help